{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:07:08Z","timestamp":1790629628406,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"French Ministry for Higher Education and Research"},{"name":"Normandy County Council\u2019, Inserm"},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Center F. Baclesse, the University of Caen Normandy"},{"name":"UNICAEN"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Identifying patients with high-grade serous ovarian cancer (HGSOC) who will respond to treatment remains a clinical challenge. We focused on miR-622, a miRNA involved in the homologous recombination repair (HRR) pathway, and we assessed its predictive value in serum prior to first-line chemotherapy and at relapse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum miR-622 expression was assessed in serum prior to first-line platinum-based chemotherapy in a prospective multicenter study (miRNA Serum Analysis, miRSA, NCT01391351) and a retrospective cohort (Biological Resource Center, BRC), and was also studied at relapse. Progression-free survival (PFS) and overall survival (OS) were used as primary and secondary endpoints prior to first-line chemotherapy and OS as a primary endpoint at relapse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The group with high serum miR-622 expression was associated with a significantly lower PFS (15.4 versus 24.4\u2009months; adjusted HR 2.11, 95% CI 1.2 3.8, P\u2009=\u20090.015) and OS (29.7 versus 40.6\u2009months; adjusted HR 7.68, 95% CI 2.2\u201326.2, P\u2009=\u20090.0011) in the miRSA cohort. In the BRC cohort, a high expression of miR-622 was also associated with a significantly lower OS (22.8 versus 35.9\u2009months; adjusted HR 1.98, 95% CI 1.1\u20133.6, P\u2009=\u20090.026). At relapse, high serum miR-622 was associated with a significantly lower OS (7.9 versus 20.6\u2009months; adjusted HR 3.15, 95% CI 1.4\u20137.2, P\u2009=\u20090.0062). Serum miR-622 expression is a predictive independent biomarker of response to platinum-based chemotherapy for newly diagnosed and recurrent HGSOC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results may open new perspectives for HGSOC patient stratification and monitoring of resistance to platinum-based and poly(ADP-ribose)-polymerase-inhibitor-maintenance therapies, facilitating better and personalized treatment decisions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/clinchem\/hvz013","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T08:47:03Z","timestamp":1580374023000},"page":"352-362","source":"Crossref","is-referenced-by-count":26,"title":["Predictive Relevance of Circulating miR-622 in Patients with Newly Diagnosed and Recurrent High-Grade Serous Ovarian Carcinoma"],"prefix":"10.1093","volume":"66","author":[{"given":"Nicolas","family":"Vigneron","sequence":"first","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9gane","family":"Vernon","sequence":"additional","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Meryet-Figui\u00e8re","sequence":"additional","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Lambert","sequence":"additional","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"},{"name":"CNRS, Normandy Delegation, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Briand","sequence":"additional","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Louis","sequence":"additional","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Krieger","sequence":"additional","affiliation":[{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Biopathology Department, Caen, France"},{"name":"Normandie Universit\u00e9, UNIROUEN, Inserm U1245, Normandy Center for Genomic and Personalized Medicine, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Medical Oncology Department and Clinical Research Unit, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Lheureux","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Blanc-Fournier","sequence":"additional","affiliation":[{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Biopathology Department, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Gauduchon","sequence":"additional","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Poulain","sequence":"additional","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Denoyelle","sequence":"additional","affiliation":[{"name":"Normandie Universit\u00e9, UNICAEN, Inserm U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France"},{"name":"UNICANCER, Cancer Center F. Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"2020021009433224200_hvz013-B1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2020021009433224200_hvz013-B2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","article-title":"Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer","volume":"14","author":"George","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2020021009433224200_hvz013-B3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2020021009433224200_hvz013-B4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejca.2017.08.029","article-title":"Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer","volume":"86","author":"Vanderstichele","year":"2017","journal-title":"Eur J Cancer"},{"key":"2020021009433224200_hvz013-B5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41571-018-0035-x","article-title":"Clinical utility of circulating non-coding RNAs\u2014an update","volume":"15","author":"Anfossi","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2020021009433224200_hvz013-B6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/14712598.2017.1340935","article-title":"Updates and current challenges in microRNA research for personalized medicine in ovarian cancer","volume":"17","author":"Mandilaras","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2020021009433224200_hvz013-B7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(16)30108-5","article-title":"Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study","volume":"17","author":"Bagnoli","year":"2016","journal-title":"Lancet Oncol"},{"key":"2020021009433224200_hvz013-B8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"2020021009433224200_hvz013-B9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ygyno.2017.10.003","article-title":"PARP inhibitors: clinical utility and possibilities of overcoming resistance","volume":"147","author":"Bitler","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2020021009433224200_hvz013-B10","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.3390\/molecules23112789","article-title":"Regulation of DNA double-strand break repair by non-coding RNAs","volume":"23","author":"Thapar","year":"2018","journal-title":"Molecules"},{"key":"2020021009433224200_hvz013-B11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","article-title":"Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer","volume":"14","author":"Choi","year":"2016","journal-title":"Cell Rep"},{"key":"2020021009433224200_hvz013-B12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.molcel.2012.02.015","article-title":"BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair","volume":"46","author":"Bunting","year":"2012","journal-title":"Mol Cell"},{"key":"2020021009433224200_hvz013-B13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"2020021009433224200_hvz013-B14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.molonc.2016.03.005","article-title":"Towards a new standardized method for circulating miRNAs profiling in clinical studies: interest of the exogenous normalization to improve miRNA signature accuracy","volume":"10","author":"Vigneron","year":"2016","journal-title":"Mol Oncol"},{"key":"2020021009433224200_hvz013-B15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin Chem"},{"key":"2020021009433224200_hvz013-B16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"2020021009433224200_hvz013-B17","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"2020021009433224200_hvz013-B18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"2020021009433224200_hvz013-B19","first-page":"293","article-title":"Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells","volume":"8","author":"Kim","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"2020021009433224200_hvz013-B20","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/gutjnl-2017-315402","article-title":"Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance","volume":"67","author":"Dietrich","year":"2018","journal-title":"Gut"},{"key":"2020021009433224200_hvz013-B21","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1080\/15384047.2015.1095402","article-title":"MicroRNA-622 acts as a tumor suppressor in hepatocellular carcinoma","volume":"16","author":"Song","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"2020021009433224200_hvz013-B22","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1007\/s13277-015-4455-2","article-title":"Upregulated miRNA-622 inhibited cell proliferation, motility, and invasion via repressing Kirsten rat sarcoma in glioblastoma","volume":"37","author":"Wang","year":"2016","journal-title":"Tumor Biol"},{"key":"2020021009433224200_hvz013-B23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.biopha.2017.09.043","article-title":"Decrease of miR-622 expression promoted the proliferation, migration and invasion of cholangiocarcinoma cells by targeting regulation of c-Myc","volume":"96","author":"Wu","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2020021009433224200_hvz013-B24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.biopha.2016.07.036","article-title":"MiR-622 functions as a tumor suppressor and directly targets E2F1 in human esophageal squamous cell carcinoma","volume":"83","author":"Song","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"2020021009433224200_hvz013-B25","doi-asserted-by":"crossref","first-page":"44222","DOI":"10.18632\/oncotarget.5826","article-title":"Foxo3a-mediated overexpression of microRNA-622 suppresses tumor metastasis by repressing hypoxiainducible factor-1\u03b1 in ERK-responsive lung cancer","volume":"6","author":"Cheng","year":"2015","journal-title":"Oncotarget"},{"key":"2020021009433224200_hvz013-B26","doi-asserted-by":"crossref","first-page":"27393","DOI":"10.18632\/oncotarget.16171","article-title":"Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer","volume":"8","author":"Ng","year":"2017","journal-title":"Oncotarget"},{"key":"2020021009433224200_hvz013-B27","doi-asserted-by":"crossref","first-page":"djv108","DOI":"10.1093\/jnci\/djv108","article-title":"Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers","volume":"107","author":"Liu","year":"2015","journal-title":"J Natl Cancer Inst"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/66\/2\/352\/32412788\/hvz013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/66\/2\/352\/32412788\/hvz013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T09:43:59Z","timestamp":1581327839000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/66\/2\/352\/5717995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1,30]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvz013","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2020,1,30]]}}}